Global Stem Cells Group announces the launch of two new stem cell treatment clinics in the cities of Arica (left) and Iquique (right) in northern Chile. The facilities are part of the international biotech company’s expanding presence in Latin America. [su_spacer] MIAMI, May 31, 2016—Global Stem Cells Group, a leading international biotechnology company, announces

  Global Stem Cells Group subsidiary Adimarket is preparing to launch Progenikine™, a new SVF closed system kit utilizing EmCyte technology, containing all the elements necessary to process adipose tissue and obtain stromal vascular fraction in a sterile environment. MIAMI, May 31—Adimarket, a subsidiary of Global Stem Cells Group, Inc. is preparing to launch Progenikine™, its

MIAMI, April 30, 2016–Global Stem Cells Group CEO Benito Novas announced that the University of Santiago has become the latest GSCG affiliate to apply for Regenerative Technologies Alliance (RTA) certification. RTA certification represents the highest standards of excellence in current medical and laboratory practices against established standards. The announcement comes less than a week after

Adimarket, a subsidiary of Global Stem Cells Group, Inc., is preparing to launch Progenikine™, its new and approved SVF closed system kit using EmCyte technology, which is expected to be available to physicians July 2016. The Progenikine kit contains all of the elements necessary to process adipose tissue and obtain stromal vascular fraction (SVF) in

MIAMI, April 30, 2016–Global Stem Cells Group and Stem Cell Training, Inc. have announced the addition of a cell assisted fat transfer training course, to be conducted by Alfredo Hoyos, M.D., head of the GSCG Advisory Board, and Enrique Testart, M.D., GSCG Chief Medical Officer. Two courses are scheduled, one to be conducted in Santiago,

MIAMI,  April 30, 2016–Global Stem Cells Group has announced the University of Santiago’s plans to endorse an alliance between GSCG and the university’s Biotechnology Lab to host an Asian-Pacific Symposium and other initiatives for potential stem cell protocol management for 2016 – 2020. The symposium will be held July 1-2 at the university in Santiago,

MIAMI, April 30, 2015–Global Stem Cells Group and the University of Santiago, Chile have announced plans to launch a new edition of the post-graduate diploma program, “Diplomat in Cell Therapy and Tissue Engineering.” The first of its kind worldwide, the program is designed for physicians and qualified practitioners to bring stem cell therapies into the

Molecular biologist, immunologist and researcher Duncan Ross, Ph.D., founder of Kimera Labs, has joined the Global Stem Cells Group Advisory Board faculty. Global Stem Cells Group CEO Benito Novas announced that Duncan Ross, Ph.D. has joined the GSCG Advisory Board. Ross is the founder of GSCG affiliate Kimera Labs in Miami. In 2004, Ross received

Global Stem Cells Group and the University of Santiago, Chile have endorsed an Asian-Pacific alliance for a regenerative medicine and stem cell symposium July 1-2 at the university’s Santiago campus and other stem cell protocol management initiatives. Through the alliance, the two organizations established a working agenda for collaborative initiatives in stem cell and regenerative

Global Stem Cells Group Advisory Board member Duncan Ross, Ph.D., founder of Kimera Research Labs, will be the keynote speaker at the Global Stem Cells Group Symposium in Santiago, Chile July 1-2, 2016. MIAMI, April 26, 2016–Global Stem Cells Group has announced that affiliate Kimera Research Labs founder Duncan Ross, Ph.D., a GSCG Advisory Board

Global Stem Cells Group and Kimera Research Labs have announced an alliance to conduct scientific research on highly manipulated cells and culture expansion, and cryopreservation of autologous stem cells. MIAMI, April 26, 2016–Global Stem Cells Group and Kimera Research Labs have announced an alliance to conduct scientific research on highly manipulated stem cells and culture

Global Stem Cells Group has announced plans to hold clinical trials, pending IRB approval, for bone marrow stem cell treatments targeting knee osteoarthritis. The trials will be held in five GSCG facilities in the U.S. and South America, with 25 patients accepted for each location. MIAMI, March 31, 2016—Pending Institutional Review Board (IRB) approval, Global

TOP